Physician profile
Mikhail Fukshansky
NPI 1699882399
$1,279.66
in general payments reported to CMS, 2019-2025
21 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $411 · 2023: $378 · 2024: $315 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $462.22 | 2022-2024 | Senza |
| Abbott Laboratories | $102.25 | 2023 | Infinity |
| Scilex Pharmaceuticals INC. | $79.10 | 2023-2025 | Ztlido |
| Amgen INC. | $75.50 | 2022-2024 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.52 | 2022-2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $66.92 | 2022 | |
| Abbvie INC. | $51.65 | 2024-2025 | |
| Ibsa Pharma INC. | $45.39 | 2023 | Licart, Tirosint |
| Horizon Therapeutics Plc | $43.47 | 2022 | |
| Globus Medical, INC. | $32.84 | 2025 | Senza |
| Novo Nordisk INC | $32.81 | 2025 | |
| Neurocrine Biosciences, INC. | $32.02 | 2024 | Ingrezza |
| Medtronic, INC. | $28.81 | 2025 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $23.61 | 2022 | |
| Ardelyx, INC. | $23.05 | 2024 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings Ltd | $21.58 | 2022 | |
| Lilly USA, LLC | $19.87 | 2025 | Zepbound, Mounjaro |
| Cequr Corporation | $18.53 | 2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $17.28 | 2023 | Verquvo, Belsomra, Steglatro |
| Antares Pharma, INC. | $16.88 | 2022 | |
| Bioventus LLC | $16.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Fukshansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.